Introduction
Methods
Study population
Diagnosis of RP-ILD and non-RP-ILD
Measurement of BAFF
Statistical analysis
Results
Participants characteristics
Parameters | NC | ASS | MDA5+ | p-value |
---|---|---|---|---|
Case number | 20 | 20 | 39 | |
Gender, female, no. (%) | 11(55%) | 14(70%) | 27(69.23%) | 0.704 |
Age, mean ± SD, years | 48.95 ± 11.71 | 54.70 ± 11.87 | 53.94 ± 13.46 | 0.834 |
Medical history, months | 10.90 ± 16.35 | 3.00 ± 2.75 | 0.051 | |
Medication | ||||
- glucocorticoids, no. (%) | 8 (40%) | 18 (46.15%) | 0.652 | |
- immunosuppressants, no. (%) | 7(35%) | 13 (33.33%) | 0.898 | |
Interstitial lung disease, no. (%) | 0.120 | |||
non-ILD | 2 (10%) | 7 (17.95%) | ||
ILD | 12 (60%) | 12 (30.77%) | ||
RP-ILD | 6 (30%) | 20 (51.28%) | ||
Myasthenia, no. (%) | 1 (5%) | 14 (35.89%) | 0.010 | |
Gottron’s sign, no. (%) | 4 (20%) | 23 (58.90%) | 0.004 | |
Heliotrope rash, no. (%) | 1 (5%) | 11 (28.20%) | 0.044 | |
V sign, no. (%) | 1 (5%) | 15 (38.46%) | 0.006 | |
Shawl sign, no. (%) | 1 (5%) | 10 (25.64%) | 0.079 | |
Periungual erythema, no. (%) | 0 (0%) | 10 (25.64%) | 0.012 | |
Skin ulcers, no. (%) | 0 (0%) | 7 (17.95%) | 0.083 | |
Mechanic’s hands, no. (%) | 4 (20%) | 13 (33.33%) | 0.284 | |
Arthritis, no. (%) | 1 (5%) | 10 (25.64%) | 0.079 | |
CK, median (range), IU/L | 64.00 (39.75–92.50) | 47.00 (29.00–105.00) | 0.659 | |
LDH, median (range), U/L | 268.50 (210.25–367.00) | 319.00 (276.00–418.00) | 0.070 | |
ESR, median (range), mm/H | 36.00 (7.00–45.00) | 36.00 (25.00–48.75) | 0.761 | |
SF, mean ± SD, ng/mL | 258.20 ± 156.77 | 916.94 ± 771.48 | 0.001 | |
CRP, median (range), mg/L | 6.30 (1.62–27.82) | 4.94 (2.30–11.40) | 0.692 | |
BAFF, mean ± SD, pg/mL | 2486.28 ± 767.97 | 2540.89 ± 1403.04 | 3882.32 ± 1880.09 | 0.001 |
Parameters | non-RP-ILD | RP-ILD | p-value |
---|---|---|---|
Case number | 19 | 20 | |
Gender, female, no. (%) | 13 (68.42%) | 14 (70%) | 0.915 |
Age, mean ± SD, years | 51.05 ± 16.05 | 56.70 ± 10.10 | 0.194 |
Medical history, months | 3.73 ± 2.90 | 2.35 ± 2.07 | 0.103 |
Medication | |||
- glucocorticoids, no. (%) | 9 (47.37%) | 9 (45%) | 0.882 |
- immunosuppressants, no. (%) | 7 (36.84%) | 6 (30%) | 0.651 |
Myasthenia, no. (%) | 5 (26.31%) | 9 (45%) | 0.224 |
Gottron’s sign, no. (%) | 13 (68.42%) | 10 (50%) | 0.242 |
Heliotrope rash, no. (%) | 5 (26.31%) | 6 (30%) | 0.798 |
V sign, no. (%) | 9 (47.36%) | 6 (30%) | 0.265 |
Shawl sign, no. (%) | 6 (31.57%) | 4 (20%) | 0.408 |
Periungual erythema, no. (%) | 5 (26.31%) | 5 (25%) | 0.925 |
Skin ulcers, no. (%) | 5 (26.31%) | 2 (10%) | 0.184 |
Mechanic’s hands, no. (%) | 6 (27.27%) | 7 (35%) | 0.821 |
Arthritis, no. (%) | 6 (21.21%) | 4 (20%) | 0.408 |
CK, median (range), IU/L | 47.00 (35.00–122.00) | 51.00 (25.50–98.25) | 0.561 |
LDH, median (range), U/L | 317.00 (253.00–418.00) | 319.00 (277.25–423.00) | 0.853 |
ESR, median (range), mm/H | 33.50 (22.00–46.50) | 41.00 (21.00–54.00) | 0.348 |
SF, median (range), ng/mL | 586.10 (453.25–876.70) | 916.40 (641.75–1121.93) | 0.692 |
CRP, median (range), mg/L | 3.96 (2.17–7.99) | 8.81 (2.93–31.88) | 0.021 |
BAFF, mean ± SD, pg/mL | 3297.28 ± 1794.69 | 4549.78 ± 1839.97 | 0.040 |
Elevated serum BAFF levels in anti-MDA5+DM
Clinical correlation of serum BAFF levels in anti-MDA5+DM
Independent predictability of BAFF to RP-ILD in anti-MDA5+DM
RP-ILD | Unadjusted | Adjusted | ||
---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | |
Gender, Female | 1.077 (0.276–4.197) | 0.915 | ||
Age | 1.034 (0.988–1.078) | 0.198 | ||
Myasthenia | 2.291 (0.595–8.825) | 0.228 | ||
Gottron’s sign | 0.462 (0.125–1.703) | 0.246 | ||
Heliotrope rash | 1.350 (0.379–4.811) | 0.643 | ||
V sign | 0.690 (0.213–2.237) | 0.536 | ||
shawl signs | 0.675 (0.174–2.614) | 0.570 | ||
Periungual erythema | 1.333 (0.341–5.208) | 0.679 | ||
arthritis | 0.674 (0.174–2.614) | 0.570 | ||
mechanic hands | 1.185 (0.382–3.675) | 0.769 | ||
skin ulcers | 0.467(0.083–2.627) | 0.387 | ||
CK, > 200 U/L | 0.593 (0.088–4.009) | 0.592 | ||
LDH, > 227 IU/L | 2.235 (0.186–26.908) | 0.526 | ||
ESR, > 21 mm/h | 1.133(0.198–6.486) | 0.888 | ||
CRP, > 8 mg/L | 3.750 (0.917–15.342) | 0.066 | 2.337 (0.487–11.228) | 0.289 |
SF, > 336.2 ng/ml | 1.373 (0.462–4.073) | 0.568 | ||
BAFF, > 2971.5 pg/ml | 11.250 (1.991–63.560) | 0.006 | 9.389 (1.609–54.769) | 0.013 |